NYSE:LLY

Eli Lilly and - LLY Stock Forecast, Price & News

$344.15

+3.65 (+1.07%)

(As of 01/31/2023 05:32 PM ET)

Add

Compare

Today's Range: $339.38
▼
$344.40
50-Day Range: $342.10
▼
$374.76
52-Week Range: $231.87
▼
$384.44

Volume: 2.41 million shs
Average Volume: 2.54 million shs
Market Capitalization: $327.00 billion

P/E Ratio: 51.67
Dividend Yield: 1.15%
Price Target: $384.11

Institutional Ownership

Eli Lilly and MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.85 Rating Score
Upside/Downside: 12.7% Upside
$384.11 Price Target
Short Interest: Healthy
0.56% of Float Sold Short
Dividend Strength: Strong
Based on Four Factors
Sustainability: -2.25
Upright™ Environmental Score
News Sentiment: 0.62
Based on 29 Articles This Week
Insider Trading: Acquiring Shares
$374.91 M Bought Last Quarter
Proj. Earnings Growth: 6.47%
From $7.73 to $8.23 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.23 out of 5 stars

Medical Sector

5th out of 1,055 stocks

Pharmaceutical Preparations Industry

4th out of 518 stocks

3.4

Analyst's Opinion

Consensus Rating
Eli Lilly and has received a consensus rating of Buy. The company's average rating score is 2.85, and is based on 11 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $384.11, Eli Lilly and has a forecasted upside of 12.7% from its current price of $340.88.
Amount of Analyst Coverage
Eli Lilly and has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

5.0

Short Interest

Percentage of Shares Shorted
0.56% of the float of Eli Lilly and has been sold short.
Short Interest Ratio / Days to Cover
Eli Lilly and has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Eli Lilly and has recently decreased by 12.28%, indicating that investor sentiment is improving significantly.

3.3

Dividend Strength

Dividend Yield
Eli Lilly and pays a meaningful dividend of 1.15%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Eli Lilly and has been increasing its dividend for 9 years.
Dividend Coverage
The dividend payout ratio of Eli Lilly and is 58.86%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Eli Lilly and will have a dividend payout ratio of 47.63% next year. This indicates that Eli Lilly and will be able to sustain or increase its dividend.

4.0

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Eli Lilly and has received a 56.49% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Peptide analogs", "Pemetrexed", "Insulin", and "SGLT2 inhibitors" products. See details.
Environmental Sustainability
The Environmental Impact score for Eli Lilly and is -2.25.

2.6

News and Social Media Coverage

News Sentiment
Eli Lilly and has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 29 news articles for Eli Lilly and this week, compared to 20 articles on an average week.
Search Interest
102 people have searched for LLY on MarketBeat in the last 30 days. This is an increase of 10% compared to the previous 30 days.
MarketBeat Follows
Only 46 people have added Eli Lilly and to their MarketBeat watchlist in the last 30 days. This is a decrease of -10% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Eli Lilly and insiders have bought 749.14% more of their company's stock than they have sold. Specifically, they have bought $374,908,350.00 in company stock and sold $44,151,279.00 in company stock.
Percentage Held by Insiders
Only 0.12% of the stock of Eli Lilly and is held by insiders.
Percentage Held by Institutions
82.13% of the stock of Eli Lilly and is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Eli Lilly and are expected to grow by 6.47% in the coming year, from $7.73 to $8.23 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Eli Lilly and is 51.18, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 131.01.
Price to Earnings Ratio vs. Sector
The P/E ratio of Eli Lilly and is 51.18, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 110.90.
Price to Earnings Growth Ratio
Eli Lilly and has a PEG Ratio of 2.09. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Eli Lilly and has a P/B Ratio of 35.62. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Eli Lilly and (NYSE:LLY) Stock

Eli Lilly and Company is a US-based multinational pharmaceutical company. It is the 12th largest pharmaceutical company by revenue and has offices in 16 countries. Its medicines are sold in at least 125 countries including its 8 blockbuster drugs. The company is a member of the S&P 500 and S&P 100 indices, it brought in roughly $5.5 billion in revenue for 2021 and employs more than 35,000 people across its network of research and production facilities.

Eli Lilly and Company was founded in 1876 by Colonel Eli Lilly. The colonel, a veteran of the Civil War, had recently dissolved an unsatisfactory partnership and set on his own to produce and develop medicinal chemicals. Colonel Lilly remained as president until his death in 1898. His charge to his family, company and coworkers was to “take what you find here and make it better and better”. The company is well-known for many drugs, including the first mass-marketing of quinine to treat malaria.

The company brought in $4,470 in its first year and saw that figure grow 10X over the next 3. Among the many innovations during this time period is the addition of gelation coatings for pills which helped set the company up for rapid expansion. The company was incorporated in 1881 as Eli Lilly and Company issuing stock to family and friends. The 1900s brought about more change for the company, change in the form of expansion which included international markets.

Advancements during the war years included increases in efficiency due to increased automation and the development of precision technologies. Among the technologies was pill manufacturing which included injecting medicines directly into a gelation capsule. This method allowed for more exact dosing, setting the standard for modern production. The company produced capsules for itself and sold excess capacity to competitors. Other major advancements include fruit flavorings in medicine, straight-line manufacturing and a method of blueprinting manufacturing tickets to prevent errors.

The modern period saw the company grow and discover new, world-class pharmaceuticals. Today, the company is engaged in the discovery, development and marketing of human pharmaceuticals. It offers a wide range of treatments, including Prozac but is perhaps most noteworthy for its work with insulin. The company is the first to mass produce insulin and has made numerous advances in treating diabetes in the time since. While other drugs are more widely known, its diabetic drugs Basaglar, Jardience, Trulicity, Humalog and Humulin are its top-sellers and contribute the bulk of revenue and cash flow.

Along with Diabetic research, the company also focuses on Alzheimer's, Oncology, Immunology, Obesity and Pain care. At the end of 2022, the company pipeline had 23 compounds in Phase 3 clinical trials and 1 in review. There were another 18 in Phase 2 trials and more than 2 dozen in Phase 1 trials. The average cost to discover a new drug was running at $2.6 billion with a 10-year discovery-to-patient timeline.

Receive LLY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eli Lilly and and its competitors with MarketBeat's FREE daily newsletter.

LLY Stock News Headlines

January 30, 2023 | marketbeat.com

Cassava Sciences Stock Undervalued with Its $124 Price Target? (LLY)

Casava Sciences Inc (NASDAQ: SAVA) stock has been the topic of much controversy in its quest for FDA approval for its simufilam drug. The Company is a

January 20, 2023 | marketbeat.com

Lilly shares slip as FDA seeks more Alzheimer's drug data

Eli Lilly shares slipped Friday morning after regulators said they need to see more data on the company’s application for a quick approval of its potential Alzheimer’s disease treatment

January 31, 2023 | Porter & Company (Ad)

Is This The End of Capitalism?

EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…

January 31, 2023 | marketwatch.com

Cytotoxic Drug Market 2023 Key Players Roche, Eli Lilly, Celgene, Sanofi

January 31, 2023 | finance.yahoo.com

Eli Lilly (NYSE:LLY) shareholders have earned a 37% CAGR over the last five years

January 31, 2023 | americanbankingnews.com

Eli Lilly and (LLY) Scheduled to Post Quarterly Earnings on Thursday

January 30, 2023 | finance.yahoo.com

FDA Gives Conditional Approval For Eli Lilly's Drug For Rare Blood Cancer

January 30, 2023 | finance.yahoo.com

Eli Lilly (LLY) Lymphoma Candidate Pirtobrutinib Gets FDA Nod

January 31, 2023 | Porter & Company (Ad)

Is This The End of Capitalism?

EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…

January 30, 2023 | finance.yahoo.com

Here’s Why Eli Lilly and Company (LLY) Rose in Q4

January 30, 2023 | finance.yahoo.com

Why Eli Lilly is tagging the Research Triangle for long-term growth

January 27, 2023 | marketwatch.com

FDA Approves Eli Lilly's Jaypirca to Treat Lymphoma Patients

January 27, 2023 | finance.yahoo.com

U.S. FDA Approves Jaypirca™ (pirtobrutinib), the First and Only Non-Covalent (Reversible) BTK Inhibitor, for Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma After at Least Two Lines of Systemic Therapy, Including a BTK Inhibitor

January 27, 2023 | finance.yahoo.com

UPDATE 1-FDA approves Eli Lilly's blood cancer drug

January 27, 2023 | seekingalpha.com

Eli Lilly wins FDA accelerated approval for lymphoma therapy

January 27, 2023 | finance.yahoo.com

Biogen (BIIB) & Eisai's Lecanemab Secures EMA's MAA Acceptance

January 27, 2023 | finance.yahoo.com

FDA Pulls EUA Granted to AstraZeneca's (AZN) Evusheld

January 26, 2023 | cnbc.com

Jim Cramer's Investing Club meeting Thursday: Stocks rise, Eli Lilly, Meta

January 26, 2023 | finance.yahoo.com

WFU receives $30M grant from the Lilly Endowment to create national network for character education

January 26, 2023 | finance.yahoo.com

Is It Too Late to Buy Eli Lilly Stock?

January 26, 2023 | finance.yahoo.com

Could This New Drug Indication Be a Winner for Eli Lilly?

January 26, 2023 | finance.yahoo.com

Lilly Supports Direct Relief’s Efforts To Expand Access to Medicines by Improving Cold Chain Capacity

January 25, 2023 | finance.yahoo.com

Why the Dip in Cassava Sciences (SAVA) Stock Shouldn’t Spook You

January 25, 2023 | benzinga.com

Here's How Much $1000 Invested In Eli Lilly 15 Years Ago Would Be Worth Today

January 25, 2023 | seekingalpha.com

Eli Lilly: Far From Dead In Alzheimer's, But Needs Help From Other Areas

January 25, 2023 | finance.yahoo.com

2 Ultra-Safe Dividend Stocks to Own in 2023

January 25, 2023 | finance.yahoo.com

Eli Lilly, Novo Nordisk Get a Share-Price Pop From Weight-Loss Drugs

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive LLY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eli Lilly and and its competitors with MarketBeat's FREE daily newsletter.

LLY Company Calendar

Last Earnings: 10/25/2021
Ex-Dividend for 12/9 Dividend: 11/14/2022
Dividend Payable: 12/09/2022
Today: 1/31/2023
Next Earnings (Confirmed): 2/02/2023
Ex-Dividend for 3/10 Dividend: 2/14/2023
Dividend Payable: 3/10/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceuticals
Sector: Medical
Current Symbol: NYSE:LLY
CUSIP: 53245710
CIK: 59478
Web: www.lilly.com
Phone: (317) 276-2000
Fax: 317-276-4878
Employees: 35,000
Year Founded: 1876

Price Target and Rating

Average Stock Price Forecast: $384.11
High Stock Price Forecast: $440.00
Low Stock Price Forecast: $286.00
Forecasted Upside/Downside: +11.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.85
Research Coverage: 13 Analysts

Profitability

EPS (Most Recent Fiscal Year): $6.66
Trailing P/E Ratio: 51.67
Forward P/E Ratio: 44.52
P/E Growth: 2.09
Net Income: $5.58 billion
Net Margins: 20.63%
Pretax Margin: 22.40%
Return on Equity: 80.80%
Return on Assets: 15.90%

Debt

Debt-to-Equity Ratio: 1.39
Current Ratio: 1.13
Quick Ratio: 0.88

Sales & Book Value

Annual Sales: $28.32 billion
Price / Sales: 11.55
Cash Flow: $9.45 per share
Price / Cash Flow: 36.42
Book Value: $9.57 per share
Price / Book: 35.96

Miscellaneous

Outstanding Shares: 950,180,000
Free Float: 949,038,000
Market Cap: $327.00 billion
Optionable: Optionable
Beta: 0.36

Social Links

Key Executives

David A. Ricks
Chairman, President & Chief Executive Officer

Anat Ashkenazi
Chief Financial Officer & Senior Vice President

Daniel M. Skovronsky
Chief Scientific Officer & Senior Vice President

Diogo Rau
Senior VP, Chief Information & Digital Officer

Alonzo Weems
Senior VP, Chief Ethics & Compliance Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

LLY Stock - Frequently Asked Questions

Should I buy or sell Eli Lilly and stock right now?: 13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly and in the last twelve months. There are currently 2 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LLY shares.
View LLY analyst ratings or view top-rated stocks.
What is Eli Lilly and's stock price forecast for 2023?: 13 equities research analysts have issued twelve-month target prices for Eli Lilly and's shares. Their LLY share price forecasts range from $286.00 to $440.00. On average, they anticipate the company's stock price to reach $384.11 in the next year. This suggests a possible upside of 12.9% from the stock's current price.
View analysts price targets for LLY or view top-rated stocks among Wall Street analysts.
How have LLY shares performed in 2023?: Eli Lilly and's stock was trading at $365.84 at the beginning of the year. Since then, LLY stock has decreased by 7.0% and is now trading at $340.21.
View the best growth stocks for 2023 here.
Are investors shorting Eli Lilly and?: Eli Lilly and saw a decrease in short interest in the month of January. As of January 15th, there was short interest totaling 4,930,000 shares, a decrease of 12.3% from the December 31st total of 5,620,000 shares. Based on an average daily trading volume, of 2,840,000 shares, the days-to-cover ratio is currently 1.7 days. Currently, 0.6% of the company's shares are sold short.
View Eli Lilly and's Short Interest.
When is Eli Lilly and's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, February 2nd 2023.
View our LLY earnings forecast.
How can I listen to Eli Lilly and's earnings call?: Eli Lilly and will be holding an earnings conference call on Thursday, February 2nd at 10:00 AM Eastern. Interested parties can register for or listen to the call using this link.
How were Eli Lilly and's earnings last quarter?: Eli Lilly and Company (NYSE:LLY) released its quarterly earnings data on Monday, October, 25th. The company reported $1.94 earnings per share for the quarter, missing the consensus estimate of $1.98 by $0.04. The company earned $6.77 billion during the quarter, compared to analyst estimates of $6.64 billion. Eli Lilly and had a trailing twelve-month return on equity of 80.80% and a net margin of 20.63%. Eli Lilly and's revenue for the quarter was up 18.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.54 EPS.
Read the conference call transcript.
How often does Eli Lilly and pay dividends? What is the dividend yield for Eli Lilly and?: Eli Lilly and announced a quarterly dividend on Monday, December 12th. Shareholders of record on Wednesday, February 15th will be given a dividend of $1.13 per share on Friday, March 10th. This represents a $4.52 annualized dividend and a dividend yield of 1.33%. The ex-dividend date of this dividend is Tuesday, February 14th. This is an increase from the stock's previous quarterly dividend of $0.98.
Read our dividend analysis for LLY.
Is Eli Lilly and a good dividend stock?: Eli Lilly and (NYSE:LLY) pays an annual dividend of $3.92 per share and currently has a dividend yield of 1.15%. The company has been increasing its dividend for 9 consecutive years, indicating the company has a new, but growing committment to grow its dividend. The dividend payout ratio is 58.86%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, LLY will have a dividend payout ratio of 47.63% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for LLY.
How will Eli Lilly and's stock buyback program work?: Eli Lilly and announced that its Board of Directors has approved a share repurchase plan on Monday, May 3rd 2021, which authorizes the company to buyback $5,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to purchase up to 2.8% of its shares through open market purchases. Shares buyback plans are generally a sign that the company's management believes its stock is undervalued.

What guidance has Eli Lilly and issued on next quarter's earnings?: Eli Lilly and issued an update on its FY23 earnings guidance on Tuesday, December, 13th. The company provided earnings per share (EPS) guidance of $8.10-8.30 for the period, compared to the consensus earnings per share estimate of $9.06. The company issued revenue guidance of $30.3-30.8 billion, compared to the consensus revenue estimate of $30.12 billion.
What is David A. Ricks' approval rating as Eli Lilly and's CEO?: 399 employees have rated Eli Lilly and Chief Executive Officer David A. Ricks on Glassdoor.com. David A. Ricks has an approval rating of 86% among the company's employees.
What other stocks do shareholders of Eli Lilly and own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Eli Lilly and investors own include Johnson & Johnson (JNJ), Pfizer (PFE), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Bristol-Myers Squibb (BMY), Walt Disney (DIS), AT&T (T), Verizon Communications (VZ) and JPMorgan Chase & Co. (JPM).
What is Eli Lilly and's stock symbol?: Eli Lilly and trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."
Who are Eli Lilly and's major shareholders?: Eli Lilly and's stock is owned by a variety of retail and institutional investors. Top institutional investors include Lilly Endowment Inc. (10.83%), Sumitomo Mitsui Trust Holdings Inc. (0.26%), New York State Common Retirement Fund (0.16%), New York State Teachers Retirement System (0.10%), Assenagon Asset Management S.A. (0.06%) and Strs Ohio (0.06%). Insiders that own company stock include Aarti S Shah, Acquisition Corp Kearny, Alfonso G Zulueta, Alonzo Weems, Donald A Zakrowski, Ilya Yuffa, Jackson P Tai, Lilly Endowment Inc, Marschall S Runge, Melissa S Barnes, Myles O'neill and Stephen F Fry.
View institutional ownership trends.
How do I buy shares of Eli Lilly and?: Shares of LLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Eli Lilly and's stock price today?: One share of LLY stock can currently be purchased for approximately $340.21.
How much money does Eli Lilly and make?: Eli Lilly and (NYSE:LLY) has a market capitalization of $323.26 billion and generates $28.32 billion in revenue each year. The company earns $5.58 billion in net income (profit) each year or $6.66 on an earnings per share basis.
How many employees does Eli Lilly and have?: The company employs 35,000 workers across the globe.
Does Eli Lilly and have any subsidiaries?: The following companies are subsidiares of Eli Lilly and: 1096401 B.C. Unlimited Liability Company, ARMO Biosciences Inc., Acanthas Pharma Inc., Advanced Cardiovascular Systems, Alnara Pharmaceuticals, Alnara Pharmaceuticals Inc., Andean Technical Operations Center, Applied Molecular Evolution Inc., AurKa Pharma Inc., Avid Radiopharmaceuticals, Avid Radiopharmaceuticals Inc., ChemGen, CoLucid Pharmaceuticals, CoLucid Pharmaceuticals Inc., Compania Farmaceutica Eli Lilly de Centro America S.A., Dermira, Dermira Canada, Dermira Inc., Devices for Vascular Intervention(DVI), Disarm Therapeutics, Disarm Therapeutics, Disarm Therapeutics Inc., Dista Ilac Ticaret Ltd. Sti., Dista S.A., Dista-Produtos Quimicos & Farmaceuticos LDA, ELCO Dominicana SRL, ELCO Insurance Company Limited, ELCO Management Inc., ELCO for Trade and Marketing S.A.E., ELGO Insurance Company Limited, Elanco Animal Health Ireland Limited, Elanco Switzerland Holding Sarl, Eli Lilly (Malaysia) Sdn. Bhd., Eli Lilly (Philippines) Incorporated, Eli Lilly (S.A.) (Proprietary) Limited, Eli Lilly (Singapore) Pte. Ltd., Eli Lilly (Suisse) S.A., Eli Lilly Asia Inc., Eli Lilly Asia Pacific SSC Sdn Bhd, Eli Lilly Australia Pty. Limited, Eli Lilly B-H d.o.o., Eli Lilly Benelux S.A., Eli Lilly Bienes y Servicios S de RL de CV, Eli Lilly CR s.r.o., Eli Lilly Canada Inc., Eli Lilly Cork Limited, Eli Lilly Danmark A/S, Eli Lilly Egypt for Trading, Eli Lilly European Clinical Trial Services SA, Eli Lilly Export S.A., Eli Lilly Finance S.A., Eli Lilly Ges.m.b.H., Eli Lilly Group Limited, Eli Lilly Holdings Ltd., Eli Lilly Hrvatska d.o.o., Eli Lilly Interamerica Inc., Eli Lilly Interamerica Inc. y Compania Limitada, Eli Lilly International Corporation, Eli Lilly Ireland Holdings Limited, Eli Lilly Israel Ltd., Eli Lilly Italia S.p.A., Eli Lilly Japan K.K., Eli Lilly Kinsale Limited, Eli Lilly Nederland B.V., Eli Lilly Nigeria Ltd., Eli Lilly Norge A.S., Eli Lilly Pakistan (Pvt.) Ltd., Eli Lilly Polska Sp.z.o.o. (Ltd.), Eli Lilly Regional Operations GmbH, Eli Lilly Romania SRL, Eli Lilly S.A., Eli Lilly Saudi Arabia Limited, Eli Lilly Services India Private Limited, Eli Lilly Slovakia s.r.o., Eli Lilly Sweden AB, Eli Lilly Vostok S.A. Geneva, Eli Lilly and Company, Eli Lilly and Company (India) Pvt. Ltd., Eli Lilly and Company (Ireland) Limited, Eli Lilly and Company (N.Z.) Limited, Eli Lilly and Company (Taiwan) Inc., Eli Lilly and Company Limited, Eli Lilly do Brasil Limitada, Eli Lilly farmacevtska druzba d.o.o., Eli Lilly y Compania de Mexico S.A. de C.V., Eli Lilly y Compania de Venezuela S.A., Glycostasis Inc., Greenfield-Produtos Farmaceuticos Lda., Heart Rhythm Technologies Inc, Hybritech, Hypnion, ICOS Corporation, ICOS Corporation, ImClone GmbH, ImClone LLC, ImClone Systems Holdings Inc., ImClone Systems LLC, Imclone Systems, Irisfarma S.A., Ivy Animal Health, LDH I Corporation, Lilly (Shanghai) Management Co. Ltd., Lilly Asia Ventures Fund I L.P., Lilly Asia Ventures Fund II L.P., Lilly Asian Ventures Fund III L.P., Lilly Cayman Holdings, Lilly Centre for Clinical Pharmacology PTE. LTD., Lilly China Research and Development Co. Ltd, Lilly Deutschland GmbH, Lilly France S.A.S., Lilly Global Nederland Holdings B.V., Lilly Global Services Inc., Lilly Holding GmbH, Lilly Holdings B.V., Lilly Hungaria KFT, Lilly Japan Financing G.K., Lilly Korea Ltd., Lilly Nederland Finance B.V., Lilly Nederland Finance B.V. - GCC, Lilly Nederland Holding B.V., Lilly Pharma Ltd., Lilly Portugal - Produtos Farmaceuticos Lda., Lilly S.A., Lilly Suzhou Pharmaceutical Co. Ltd., Lilly Trading Co. LTD, Lilly USA LLC, Lilly Ventures Fund I LLC, Lilly del Caribe Inc., Lilly ilaç ticaret limited şirketi, Lohmann Animal Health, Loxo Oncology, Loxo Oncology Inc., Novartis Animal Health, OY Eli Lilly Finland AB, Origin Medsystems, PT. Eli Lilly Indonesia, Pacific Biotech, Petra Pharma Corporation, Pharmaserve-Lilly S.A.C.I., Pharmaserve-Lilly S.A.C.I., Physio-Control, Prevail Therapeutics Inc., Protomer Technologies, SGX Pharmaceuticals, SGX Pharmaceuticals Inc., Spaly Bioquimica S.A., UAB Eli Lilly Lietuva, Valquifarma S.A., and Vital Pharma Productos Farmaceuticos.
Read More
How can I contact Eli Lilly and?: Eli Lilly and's mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The official website for the company is www.lilly.com. The company can be reached via phone at (317) 276-2000, via email at johnson_philip_l@lilly.com, or via fax at 317-276-4878.

This page (NYSE:LLY) was last updated on 1/31/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Eli Lilly and - LLY Stock Forecast, Price & News

Eli Lilly and MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Eli Lilly and (NYSE:LLY) Stock

LLY Stock News Headlines

LLY Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

LLY Stock - Frequently Asked Questions

Overall MarketRank^™